News & Updates
Showing Pharmacy articles
Showing

Mid-dose beta-blocker therapy tied to highest mortality reduction after AMI
Use of any beta-blocker dose results in a significant decrease in mortality following acute myocardial infarction (AMI) when compared with no treatment, reports a study. Doses >25 percent to 50 percent of the currently recommended target dose (RTD) are associated with highest mortality reduction within the first year after AMI, indicating that higher doses are not required.

Bisphosphonate, denosumab not linked to acute cardiovascular risk
Use of oral bisphosphonate or denosumab does not appear to increase the risk of cardiovascular events (CVEs), namely acute myocardial infarction, unstable angina, cerebrovascular accident, and transient ischemic attack, in persons with incident fracture, a study has shown.

Molnupiravir cuts hospitalization, death in COVID-19 patients at high risk of progression
An emulation of a randomized target trial suggests that molnupiravir may reduce hospital admission or death in adults who have tested positive for COVID-19 during the predominance of Omicron who were at high risk of progression to severe disease.






